[
  {
    "ts": null,
    "headline": "$92.91 Bn Nasal Drug Delivery Market Trends, Opportunities, and Forecasts, 2020-2024 & 2025-2030F",
    "summary": "The Global Nasal Drug Delivery Market presents opportunities driven by increased patient preference for non-invasive methods, rising chronic respiratory conditions, and innovations in nose-to-brain drug delivery for CNS treatments. Key players like GlaxoSmithKline and Pfizer are optimizing formulations to overcome permeability challenges. Nasal Drug Delivery Market Nasal Drug Delivery Market Dublin, Nov. 28, 2025 (GLOBE NEWSWIRE) -- The \"Nasal Drug Delivery Market - Global Industry Size, Share,",
    "url": "https://finnhub.io/api/news?id=2348fd6285424a6b268a831ac81a874c4b5a9844256f89201084a7eee746b64f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764332940,
      "headline": "$92.91 Bn Nasal Drug Delivery Market Trends, Opportunities, and Forecasts, 2020-2024 & 2025-2030F",
      "id": 137628276,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Global Nasal Drug Delivery Market presents opportunities driven by increased patient preference for non-invasive methods, rising chronic respiratory conditions, and innovations in nose-to-brain drug delivery for CNS treatments. Key players like GlaxoSmithKline and Pfizer are optimizing formulations to overcome permeability challenges. Nasal Drug Delivery Market Nasal Drug Delivery Market Dublin, Nov. 28, 2025 (GLOBE NEWSWIRE) -- The \"Nasal Drug Delivery Market - Global Industry Size, Share,",
      "url": "https://finnhub.io/api/news?id=2348fd6285424a6b268a831ac81a874c4b5a9844256f89201084a7eee746b64f"
    }
  },
  {
    "ts": null,
    "headline": "8 'Safer' Dividend Buys In Barron's 23 Better November Bets Than T-Bills",
    "summary": "Eight of the top fifteen Barron's Better Bets (BBB) 'Safer' dividend stocks, including Conagra, Altria, and Verizon, are currently attractively priced for income investors. Read more here.",
    "url": "https://finnhub.io/api/news?id=2eac5944ea959165c6c1fe24e57aec69affc019dafbdaa597dd49cb3c314f9f2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764327611,
      "headline": "8 'Safer' Dividend Buys In Barron's 23 Better November Bets Than T-Bills",
      "id": 137629788,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/94737106/image_94737106.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Eight of the top fifteen Barron's Better Bets (BBB) 'Safer' dividend stocks, including Conagra, Altria, and Verizon, are currently attractively priced for income investors. Read more here.",
      "url": "https://finnhub.io/api/news?id=2eac5944ea959165c6c1fe24e57aec69affc019dafbdaa597dd49cb3c314f9f2"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer Stock Underperforming the Dow?",
    "summary": "While Pfizer has lagged behind the broader Dow Jones Industrial Average, Wall Street remains optimistic about the stock.",
    "url": "https://finnhub.io/api/news?id=a4847fa8f7cdd1d26c1983abccad9513f89d1b3d002db443df16b107447540c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764315276,
      "headline": "Is Pfizer Stock Underperforming the Dow?",
      "id": 137628277,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "While Pfizer has lagged behind the broader Dow Jones Industrial Average, Wall Street remains optimistic about the stock.",
      "url": "https://finnhub.io/api/news?id=a4847fa8f7cdd1d26c1983abccad9513f89d1b3d002db443df16b107447540c0"
    }
  },
  {
    "ts": null,
    "headline": "Guggenheim Lifts PT on Pfizer Inc. (PFE) to $35 From $33, Keeps a Buy Rating",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the best low volatility large cap stocks to invest in. On November 24, Guggenheim lifted the price target on Pfizer Inc. (NYSE:PFE) to $35 from $33 while keeping a Buy rating on the stock. The firm told investors that Pfizer Inc.’s (NYSE:PFE) acquisition of Metsera, Inc. marks a “a […]",
    "url": "https://finnhub.io/api/news?id=475aae0acff537b2150956b2a94ec91ed2522fb282faed16137c9ae742f9d454",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764314380,
      "headline": "Guggenheim Lifts PT on Pfizer Inc. (PFE) to $35 From $33, Keeps a Buy Rating",
      "id": 137628278,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the best low volatility large cap stocks to invest in. On November 24, Guggenheim lifted the price target on Pfizer Inc. (NYSE:PFE) to $35 from $33 while keeping a Buy rating on the stock. The firm told investors that Pfizer Inc.’s (NYSE:PFE) acquisition of Metsera, Inc. marks a “a […]",
      "url": "https://finnhub.io/api/news?id=475aae0acff537b2150956b2a94ec91ed2522fb282faed16137c9ae742f9d454"
    }
  }
]